SHR-A1811 for Injection Clinical Trials

5 actively recruiting trials

Also known as: SHR-A1811 group

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 2

Top Sponsors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.3
Jiangsu HengRui Medicine Co., Ltd.1
Henan Cancer Hospital1

Indications

Cancer5
Breast Cancer3
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1
HER2 Low Breast Carcinoma1
Early-stage or Locally Advanced HER2-positive Breast Cancer1

Other5 trials

A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor

Phase 1

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

Phase 2

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Phase 2

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.